Home > Neurology > ECF 2020 > ECF Round-Up Articles > No support for IVIG as treatment of acute attacks in NMOSD

No support for IVIG as treatment of acute attacks in NMOSD

Presented By
Dr De-Cai Tian, Capital Medical University, China
ECF 2020
Results of a retrospective study from China did not support treatment with intravenous immunoglobulin (IVIG) alone as a first-line option for acute attacks of neuromyelitis optica spectrum disorders (NMOSD). However, the addition of IVIG therapy to high-dose intravenous steroids may be superior to steroids alone for NMOSD patients with high Expanded Disability Status Scale (EDSS) scores at onset. Because NMOSD is an inflammatory autoimmune syndrome of the CNS with devastating clinical outcomes, adequate treatment of early attacks is decisive to prevent severe disability. The first-line treatment for acute attacks is high-dose intravenous steroid therapy. Therapeutic plasma exchange and immunoadsorption serve to remove plasma components involved in the inflammation. IVIG has been used for the treatment of a number of autoimmune disorders with various efficacy, but has not produced consistent results for acute attacks in immune-mediated demyelinating disease...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on